rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'triton3']
 #gu23 presents triton3 results showing rpfs benefit of rucaparib vs other tx in mcrpc w/ddr mutations. notably distinct effects in brca subgroup (+) vs. atm (no effect). quite interesting! 
Prostate cancer medical oncologist and physician-scientist, Kendrick Family Chair for Prostate Cancer Research, Cleveland Clinic. Posts are my own.